Presented by Mohamed Hassanein, Director, Translational Medicine at Pfizer

1. Current therapeutic landscape: drug types, mechanisms, and limitations

2. Precision medicine approach using genomic, microbiome, and immunologic data for personalized therapies

3. The future research and innovation outlook

Presented by Thomas Hach, Director Healthcare Systems at Novartis

•  Complications with sampling
•  Testing on assay sensitivity
• Early clinical utility studies- collecting the package of 
  evidence

•  Preclinical Validation
• Analytical and Clinical Validation
• Regulatory Pathways
•  Biomarker Identification

•  The development of novel multiplexed imaging technologies
• Considerations for choosing multiplex assays
• Practical tips for implementation

• Explore the role of liquid biopsy in tailoring precision medicine approaches for individual cancer patients
• Overcoming current challenges and limitations associated with biopsy techniques
• Exploring tumor heterogeneity

• IVDR regulations 
  
  

 •Biomarker specificity
• Regulatory hurdles
• Patient engagement